Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;18(6):2100173.
doi: 10.1080/21645515.2022.2100173. Epub 2022 Sep 26.

Information systems for vaccine safety surveillance

Affiliations
Review

Information systems for vaccine safety surveillance

Jim P Buttery et al. Hum Vaccin Immunother. .

Abstract

Immunization implementation in the community relies upon post-licensure vaccine safety surveillance to maintain safe vaccination programs and to detect rare AEFI not observed in clinical trials. The increasing availability of electronic health-care related data and correspondence from both health-related providers and internet-based media has revolutionized health-care information. Many and varied forms of health information related to adverse event following immunization (AEFI) are potentially suitable for vaccine safety surveillance. The utilization of these media ranges from more efficient use of electronic spontaneous reporting, automated solicited surveillance methods, screening various electronic health record types, and the utilization of natural language processing techniques to scan enormous amounts of internet-based data for AEFI mentions. Each of these surveillance types have advantages and disadvantages and are often complementary to each other. Most are "hypothesis generating," detecting potential safety signals, where some, such as vaccine safety datalinking, may also serve as "hypothesis testing" to help verify and investigate those potential signals.

Keywords: health informatics; public health; surveillance; vaccine safety; vaccinology.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Potential vaccine safety data sources by severity of presentation.

References

    1. Buttery JP. Developing standard safety outcomes for COVID-19 vaccines. Vaccine. 2021;39(22):1–7. doi:10.1016/j.vaccine.2021.03.004. - DOI - PMC - PubMed
    1. Danchin M, Buttery J. COVID-19 vaccine hesitancy: a unique set of challenges. Intern Med J. 2021;51(12):1987–1989. doi:10.1111/imj.15599. - DOI - PMC - PubMed
    1. Kurth R. [Infectious diseases: how big is the real danger? Interview by Strehlow Karen. Dtsch Med Wochenschr. 2005;Suppl 1:64–65. - PubMed
    1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840. - DOI - PMC - PubMed
    1. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt A-H, Skattør TH, Tjønnfjord GE, et al. Thrombosis and Thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. doi:10.1056/NEJMoa2104882. - DOI - PMC - PubMed

MeSH terms